Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy
Open accessThe DOI matches its Crossref record; 20 of the 22 references it cites were found in a registry or an index.
Abstract
Introduction We evaluated the ability of histopathologic response criteria to predict overall survival (OS) and disease-free survival (DFS) in patients with surgically resected non-small cell lung cancer (NSCLC) treated with or without neoadjuvant chemotherapy.Methods Tissue specimens from 358 patients with NSCLC were evaluated by pathologists blinded to the patient treatment and outcome. The surgical specimens were reviewed for various histopathologic features in the tumor including percentage of residual viable tumor cells, necrosis, and fibrosis. The relationship between the histopathologic findings and OS was assessed.Results The percentage of residual viable tumor cells and surgical pathologic stage were associated with OS and DFS in 192 patients with NSCLC receiving neoadjuvant chemotherapy in multivariate analysis (p = 0.005 and p = 0.01, respectively). There was no association of OS or DFS with percentage of viable tumor cells in 166 patients with NSCLC who did not receive neoadjuvant chemotherapy (p = 0.31 and p = 0.45, respectively). Long-term OS and DFS were significantly prolonged in patients who had ≤10% viable tumor compared with patients with >10% viable tumor cells (5 years OS, 85% versus 40%, p < 0.0001 and 5 years DFS, 78% versus 35%, p < 0.001).Conclusion The percentages of residual viable tumor cells predict OS and DFS in patients with resected NSCLC after neoadjuvant chemotherapy even when controlled for pathologic stage. Histopathologic assessment of resected specimens after neoadjuvant chemotherapy could potentially have a role in addition to pathologic stage in assessing prognosis, chemotherapy response, and the need for additional adjuvant therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prespecified boundary for a treatment arm to be considered promising for further testing was ≥6 MPRs in 21 evaluable patients for each arm, based on historical controls for neoadjuvant platinum-based chemotherapy that yielded a response rate of approximately 15%4.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The realization that a positive association exists between an MPR (≤10% viable tumor in resected tumor specimens) to neoadjuvant chemotherapy and improved survival outcomes in patients with operable NSCLC4–7”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [4]
In the citing paper
“Historically, neoadjuvant chemotherapy has resulted in MPR rates between 7% and 27% in localized NSCLC4,6,7,12,13.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [4]
In the citing paper
“a target response that is superior to the one observed after induction platinum-based chemotherapy alone of 15% (as observed in MD Anderson historical controls4).”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,798
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., De Rosa, F., Milanowski, J., Karnicka-Mlodkowski, H., Pesek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 881
The New Lung Cancer Staging System
Detterbeck, F. C., Boffa, D. J., & Tanoue, L. T. (2009) · Chest · doi:10.1378/chest.08-0978 · Cited by 817
Depierre, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.247 · Cited by 626
Betticher, D. C., Hsu Schmitz, S.-F., Tötsch, M., Hansen, E., Joss, C., von Briel, C., Schmid, R. A., Pless, M., Habicht, J., Roth, A. D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.040 · Cited by 449 · cited 3×
“DISCUSSION Although the survival benefits of neoadjuvant chemotherapy remain controversial, it has been observed that pathologic response after neoadjuvant therapy in patients with resected stage IIIA NSCLC is associated with improved oS.(8) In a multicenter, phase II trial evaluating pN2 patients treated with three c…”
BackgroundInfluentialRoth, J. A., Atkinson, E. N., Fossella, F., Komaki, R., Ryan, M. B., Putnam, J. B., Lee, J. S., Dhingra, H., De Caro, L., Chasen, M., et al. (1998) · Lung Cancer · doi:10.1016/s0169-5002(98)00046-4 · Cited by 447
Self-citationROSELL, R., GOMEZCODINA, J., CAMPS, C., JAVIERSANCHEZ, J., MAESTRE, J., PADILLA, J., CANTO, A., ABAD, A., & ROIG, J. (1999) · Lung Cancer · doi:10.1016/s0169-5002(99)00045-8 · Cited by 393
Bepler, G., Kusmartseva, I., Sharma, S., Gautam, A., Cantor, A., Sharma, A., & Simon, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1101 · Cited by 333 · cited 1×
“It has also been reported that high expression levels of excision repair crosscomplementation group 1 protein and ribonucleotide reductase predict resistance to platinum or gemcitabine chemotherapy.(18,19) The histopathologic response reported in this article may form a surrogate end point for survival in phase II cli…”
BackgroundCeppi, P., Volante, M., Novello, S., Rapa, I., Danenberg, K. D., Danenberg, P. V., Cambieri, A., Selvaggi, G., Saviozzi, S., Calogero, R., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl300 · Cited by 323 · cited 1×
“It has also been reported that high expression levels of excision repair crosscomplementation group 1 protein and ribonucleotide reductase predict resistance to platinum or gemcitabine chemotherapy.(18,19) The histopathologic response reported in this article may form a surrogate end point for survival in phase II cli…”
Background
Cited by
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
“These results, requiring validation in larger trials, suggest that pathologic response after neoadjuvant immunotherapy may be an early surrogatemarker for long-term clinical outcomes, similar to the general experiencewithneoadjuvant chemotherapies inbreast and lung cancer (11, 12).”
BackgroundMethodResultInfluential
Metadata
- Authors
- Pataer, A., Kalhor, N., Correa, A. M., Raso, M. G., Erasmus, J. J., Kim, E. S., Behrens, C., Lee, J. J., Roth, J. A., Stewart, D. J., Vaporciyan, A. A., Wistuba, I. I., & Swisher, S. G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Pataer, Apar
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 7
- Issue
- 5
- Pages
- 825-832
- ISSN
- 1556-0864 (ISSN-L)
- PMC
- PMC3465940
- OpenAlex
- W1988160404
- Cited by
- 374
- References
- 22
- Citations by year
- 2026: 25 · 2025: 25 · 2024: 42 · 2023: 54 · 2022: 52 · 2021: 65 · 2020: 34 · 2019: 23 · 2018: 18 · 2017: 4 · 2016: 6 · 2015: 4 · 2014: 16 · 2013: 5 · 2012: 1
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1310 d)
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA070907, P01CA078778, P30CA016672)
- National Center for Research Resources (UL1RR024148)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- non-small cell lung cancer, neoadjuvant chemotherapy, overall survival, disease-free survival, prognostic factors, surgical resection, tumor necrosis, tumor fibrosis, pathological stage
- MeSH terms
- Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Combined Modality Therapy, Cross-Sectional Studies, Deoxycytidine, Etoposide, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Survival Rate, Carboplatin, Chemotherapy, Adjuvant, Paclitaxel, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy. https://app.cochat.ai/papers/10.1097/jto.0b013e318247504a
- The paper
- Pataer, A., Kalhor, N., Correa, A. M., Raso, M. G., Erasmus, J. J., Kim, E. S., Behrens, C., Lee, J. J., Roth, J. A., Stewart, D. J., Vaporciyan, A. A., Wistuba, I. I., & Swisher, S. G. (2012). Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy. Journal of Thoracic Oncology. https://doi.org/10.1097/jto.0b013e318247504a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.